Category Archives: Recent News

BriaCell Therapeutics Announces Closing of $8.5 Million Offering

Philadelphia & Vancouver, British Columbia – September 12, 2024 – BriaCell Therapeutics Corp. (Nasdaq: BCTX, ...

BriaCell Therapeutics Announces $8.5 Million Offering Priced At-the-Market Under Nasdaq Rules

Philadelphia & Vancouver, British Columbia – September 11, 2024 – BriaCell Therapeutics Corp. (Nasdaq: BCTX, ...

BriaCell Reports Positive Overall Survival (OS) in Metastatic Breast Cancer

• Median overall survival of 15.6 months in Phase 2 Bria-IMT™ study patients treated in ...

BriaCell Announces Positive Pre-IND Meeting with FDA for Bria-PROS+™ for Prostate Cancer

• BriaCell has received positive feedback from its Pre-Investigational New Drug Application (Pre-IND) meeting with ...

BriaCell Announces Presentation at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting

PHILADELPHIA, PA and VANCOUVER, British Columbia, September 9, 2024— BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) ...

BriaCell Quadruples Progression Free Survival (PFS) in Patient with “Eye-Bulging” Metastatic Breast Cancer

Progression free survival (PFS) extended to 9.1 months in ADC resistant patient – quadruple the ...

BriaCell Presents Clinical Efficacy Data at ASCO 2024

BriaCell doubles Progression-Free-Survival (PFS) and Clinical Benefit Rate vs historical results in the literature Bria-IMT™ ...

BriaCell Initiates Patient Enrollment in First-in-Human Study of Bria-OTS(TM) in Advanced Metastatic Breast Cancer

PHILADELPHIA and VANCOUVER, British Columbia, May 30, 2024 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (NASDAQ: ...

BriaCell Announces Clinical Supply Agreement with BeiGene for Bria-OTS(TM) First in Human Study

Study to evaluate the effects of Bria-OTS™ in combination with anti-PD-1 antibody tislelizumab, in advanced, ...

BriaCell Doubles Progression-Free-Survival (PFS) and Reports Clinical Benefit Data at ASCO 2024

83% intracranial objective response rate (iORR) with Bria-IMT™ in heavily pretreated advanced breast cancer patients ...